First authors of the article -Jeff Weitz/Hamilton Health Sciences; Robert Harrington/Weill Cornell Medicine
May 2, 2026, 13:10
Targeting FXIa As a Safer Anticoagulant Target Than FXa in LIBREXIA Trial – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by et al, adding:
”Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
This narrative review details the pharmacological rationale for targeting FXIa as a safer anticoagulant target than FXa, and outlines how phase 2 findings informed milvexian dosing regimens across three phase 3 LIBREXIA trials enrolling approximately 50,000 patients with AF, ACS, or ischemic stroke.”
Title: Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
Authors: Jeff Weitz, Robert Harrington on behalf of the LIBREXIA Program Executive Council
Stay updated on all scientific advances with Hemostasis Today.
-
May 2, 2026, 10:35Alessandra Bosch: First Comprehensive Swiss Haemophilia Registry Report Now Published
-
May 2, 2026, 10:24From Gene Mutation to Clot Risk in Factor V Leiden – ICHCC
-
May 2, 2026, 10:15Omid Seidizadeh: Enhancing Diagnostic Strategies for von Willebrand Disease Worldwide
-
May 2, 2026, 10:09Scott McLean: Fewer Bleeds Do Not Always Mean a Better Life in Bleeding Disorders
-
May 2, 2026, 10:01Islam Arid: A Practical Guide to ECMO in Modern Intensive Care
-
May 2, 2026, 09:54The West Virginia Department of Health Announces the Stroke Smart West Virginia Initiative
-
May 2, 2026, 09:38Kim Gannon: Stroke Is Treatable and Outcomes Are Dramatically Better When We Act Fast
-
May 2, 2026, 09:19Rajan Gadhia: Many Strokes Are Preventable with Awareness, Early Recognition, and Timely Action
-
May 2, 2026, 08:34Gary Kurdziel: Closing the Gap Between Onset and Insight in Stroke Care